July 7th to 9th 2022

Workshop & Symposium

„Tumor Immunology meets Oncology XVI“

Institute of Medical Immunology
Prof. Dr. Barbara Seliger

WELCOME TO HALLE (SAALE)
Dear colleagues and friends,

once again it is a great pleasure for us to welcome you in Halle for our meeting „Tumor immunology meets oncology (TIMO XVI)“, which is now held after two years of break due to the corona pandemic. We decided to make it as a presence meeting, since TIMO is living next to the talks and exchange of unpublished results from vibrant scientific discussions in a relaxed atmosphere combining high-end research, friendship and culture. This year, we expect again an exceptional participation due to the growing number of immunotherapies.

The meeting focusses on immune escape mechanisms resulting in immune tolerance, the role of immune effector and suppressor cells and the composition of the tumor microenvironment. In addition, novel strategies will be presented in order to revert the immune escape and improve the efficacy of immunotherapies.

This meeting attracts a broad range of participants and will link basic, translational as well as clinical research. Although some cancer immunotherapies have recently been successfully implemented for the treatment of many tumor entities, there is still much to do in order to increase therapy response and reprogram immune inhibitory properties of the tumor and its environment mechanisms.

This meeting brings together an extraordinary group of international and national scientists and clinicians. In addition, it represents the main activity of the working group “Tumor immunology” of the German Society of Immunology with the aim to also outreach young researchers in this field to understand anti-tumor immune responses, to treat different cancers with distinct immunotherapeutic approaches thereby promoting young scientists/clinicians to present their own work.

We would like to thank you for coming to Halle and we hope that you leave the conference with novel insights for your own basic and translational research as well as with impressions of the beauty and hospitality of the city.

We express our gratitude to all who were involved in the organization of this event. Thank you for the meeting attendees to join this event.

---

General information

The TIMO registration desk is located in the lobby of the Steintor-Varieté. Faculties and/or companies are required to upload their presentation not later than half an hour before the session starts in the glass foyer.

Poster session will take place at the 7th of July from 05.00 p.m. It offers an opportunity for continued network and provides education in a relaxed atmosphere, where attendees can interact with poster presenters one by one. The three best talks in the workshop and posters will be selected by a jury and awarded prizes.
**Workshop program „Tumor immunology“**

**Date:** 7th of July 2022  
**Venue:** Steintor-Varieté Halle, glass foyer

12.45 – 01.00 p.m.  
**Introduction**  
Barbara Seliger

**Chair:** Dagmar Riemann (Halle, GER)  
Michael Bachmann (Dresden, GER)

01.00 – 01.15 p.m.  
**Novel function of miRNAs: Up regulation of the antigen processing and presentation pathway by overexpression of miR-155-5p**  
Yuan Wang (Halle, GER)

01.15 – 01.30 p.m.  
**miRNAs capable of reversing immune escape mechanisms**  
Theresa Kordaß (Heidelberg, GER)

01.30 – 01.45 p.m.  
**Impact of PD-1 and/or TIGIT deletion in melanoma-specific CD8+ T lymphocytes**  
Gwenann Cadiou (Nantes, FR)

01.45 – 02.00 p.m.  
**Extended oxidation for therapy and immunomodulation in cancer**  
Sander Bekeschus (Greifswald, GER)

02.00 – 02.15 p.m.  
**GDF-15 – a cytokine and its immunomodulatory potential**  
Beatrice Haack (Würzburg, GER)

02.15 – 02.30 p.m.  
**Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer**  
Luise Müller (Dresden, GER)

02.30 – 03.00 p.m. **Coffee break**

**Chair:** Nathalie Labarriére (Nantes, FR)  
Ofer Mandelboim (Jerusalem, ISR)

03.00 – 03.15 p.m.  
**Blocking MCT4 reverses lactic acid-driven immunosuppression and augments checkpoint therapy in colon cancer in vitro and in vivo**  
Nathalie Babl (Regensburg, GER)

03.15 – 03.30 p.m.  
**Human ovarian cancer ascites impairs anti-tumor effector functions of NK cells**  
Antonio Hrvat (Essen, GER)

03.30 – 03.45 p.m.  
**Personalized treatment testing for head and neck cancer patients**  
Ahmed Al-Samadi (Helsinki, FIN)

03.45 – 04.00 p.m.  
**The breast cancer tumor microenvironment in sub-Saharan Africa reveals features associated with worse survival among West African patients**  
Marcus Bauer (Halle, GER)

04.00 – 04.15 p.m.  
**Co-stimulatory bispecific antibodies induce enhanced T cell activation and tumor cell killing in breast cancer models**  
Karsten M. Warwas (Heidelberg, GER)

04.15 – 04.30 p.m.  
**Adapter CARs: Estimation of the affinity between adapter and CAR domain required for function**  
Tabea Bartsch (Dresden, GER)
WORKSHOP PROGRAM

04.30 – 04.45 p.m.
Epigenetic immune cell quantification for prognosis and monitoring of patients with B cell Non-Hodgkin’s lymphoma
Christoph Sachsenmaier (Berlin, GER)

04.45 – 05.00 p.m.
Simple and high-throughput high dimensional cytometry: Introducing the CyTOF XT™
Shaghayegh Derakhshani (München, GER)

Chair:   Veronica Huber (Milano, ITA)
         Marc Schmitz (Dresden, GER)

05.00 – 06.45 p.m.
Poster session

Friday, 08th of July 2022
08.00 p.m.
Networking event Steintor-Varieté Halle
Come Together

Poster session „Tumor immunology”

Date:    7th of July 2022, 05.00 – 07.00 p.m.
Venue:   Steintor-Varieté Halle, glass foyer

Chair:   Veronica Huber (Milano, ITA)
         Marc Schmitz (Dresden, GER)

1. Repeated oxidative stress in skin cancer cells
Julia Berner (Greifswald, GER)

2. Oxidized ovalbumin augment T-cell activation and provides protection against Ova-expressing tumors
Ramona Clemen (Greifswald, GER)

3. Transient melanoma phenotype switching sustains immunogenicity upon innate immune receptor activation
Beatrice Thier (Essen, GER)

4. IDO1 inhibition combats immune cell exclusion through inducing cell migration while PD-1 blockage increases IL-6 and -8 secretion from the T cells in head and neck cancer
Meri Sieviläinen (Helsinki, FIN)

5. Comparison of two structurally different RevTMs for the RevCAR system to specifically target CEA expressing cells
Karla Gonzalez Soto (Dresden, GER)

6. Reprogramming of tumor-associated macrophages to improve immunotherapy of solid tumors
Luísa Vieira Codeço Marques (Heidelberg, GER)

7. Evaluation of antibody and cellular immune response after booster vaccination with RBD based vaccines in patients with malignancies
Rocmira Perez (Havana, CUB & Halle, GER)
8. The function of lapatinib and erlotinib in EGFR-related pathways and their immune-modulatory effects in head and neck squamous cell carcinoma
Bo Yang (Halle, GER)

9. Time-dependent altered changes of neoplastic features in JAK2-mutated cells upon JAK1/JAK2 inhibition
Marcus Bauer (Halle, GER)

10. FocuSCOPE: A multi-omics solution to simultaneously analyze genetic variants and transcriptomes in single cells
Ritika Kulshreshtha (Köln, GER)

11. Melanoma cell-derived extracellular vesicles (EVs) induce tumor-associated macrophages (TAMs) by the transport of miRNAs
Dennis Gerloff (Halle, GER)

12. *In vitro* validation of Glypican-1 as a novel potential target for antibody- or CAR-based therapies of triple-negative breast cancer (TNBC)
Claudia Müller (Leipzig, GER)

13. Modulating tumor-associated neutrophils augments response to immune checkpoint therapy
Benedict Boateng Antuamwine (Essen, GER)

14. Immune landscape of the tumor microenvironment in Ethiopian breast cancer patients
Meron Yohannes (Addis Ababa, ETH)

15. Identification of PD-L1 regulating miRNAs and their prognostic significance in melanoma patients
Christoforos Vaxevanis (Halle, GER)

16. Neoadjuvant chemotherapy is associated with enhanced pro-inflammatory functionality of intratumoral CD4+ T cells in pancreatic cancer
Max Heiduk (Dresden, GER)
11.45 – 12.15 p.m.
A screening system for immune checkpoints on dendritic cells
Oliver Kepp (Villejuif, FR)

12.15 – 12.45 p.m.
Individualizing Immunotherapy in CRC
Dirk Jäger (Heidelberg, GER)

12.45 – 01.40 p.m.
LUNCH BREAK AND POSTER VIEWING

01.40 – 01.45 p.m.
Keynote lecture
Introduction: Barbara Seliger

01.45 – 02.15 p.m.
Fusubacterium nucleatum: from tooth to tumors
Ofer Mandelboim (Tel Aviv, ISR)

Session: NK cells from basic to the clinics
Chair: Sergio Rutella/ Douglas McNeel

02.15 – 02.45 p.m.
Combinations of HLA and NK receptors in disease
John Trowsdale (Cambridge, GBR)

02.45 – 03.15 p.m.
NK cells in solid tumors
Adelheid Cerwenka (Mannheim, GER)

03.15 – 03.45 p.m.
From CAR T to off the shelf CAR NK cells for tumor retargeting
Ulrike Köhl (Leipzig, GER)

03.45 – 04.15 p.m. Coffee break

Session: Novel insights into immunotherapy of melanoma
Chair: Sylvia Adams/ Lorenzo Galluzzi

04.15 – 04.45 p.m.
NFATc2 in melanoma cells: tumor biology meets epigenetics and immunotherapy
Andrea Anichini (Milano, ITA)

04.45 – 05.15 p.m.
Optimizing T cells for adoptive cell transfer approaches in melanoma
Nathalie Labarrière (Nantes, FR)

05.15 – 05.45 p.m.
Reversed personalized medicine in metastatic melanoma
Gal Markel (Petah Tikva, ISR)

05.45 – 06.15 p.m.
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma
Michele Maio (Siena, ITA)

Friday, 08th of July 2022
08.00 p.m. DINNER for all
Networking event
Steintor-Variété Halle
Session: Immunotherapies I

Introduction:

08.15 – 08.30 a.m.
Where are we? Where are we going? Where should we go?
In: Immuno-Oncology
Stefan Glück (Florida, USA)

08.30 – 09.00 a.m.
Novel strategies for functional reprogramming of myeloid cells in cancer patients
Veronica Huber (Milano, ITA)

09.00 – 09.30 a.m.
Immune signatures for characterization and prediction of responses of solid tumors to treatments with radiotherapy in combination with immune therapies
Udo Gaipl (Erlangen, GER)

09.30 – 10.00 a.m.
Modulating anti-tumor immunity in breast cancer to increase survival
Sylvia Adams (New York, USA)

10.00 – 10.30 a.m.
Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer
Lorenzo Galluzzi (New York, USA)

10.30 – 11.00 a.m. Coffee break

Session: Immunotherapies II

Chair: Gal Markel/ Marco Gerlinger

11.00 – 11.30 a.m.
Impact of KRAS oncogene signaling on the tumour immune microenvironment in lung cancer: potential therapeutic implications
Miriam Molina-Arcas (London, GBR)

11.30 – 12.00 a.m.
DNA vaccines as treatment for prostate cancer – mechanisms of action and resistance
Douglas McNeel (Madison, USA)

12.00 – 12.30 p.m.
Immune effector senescence and treatment response in acute myeloid leukemia
Sergio Rutella (Nottingham, GBR)

12.30 – 01.00 p.m.
Wrap up and closing remarks
Jörg Wischhusen (Würzburg, GER)
REGISTRATION FEE:

300 € - payable until 24th of June 2022 or cash at the registration desk. MLU members will be charged for 200 € (Clinicians, PhD), 100 € (external students), MLU Bachelor/Master students for free (please bring in your MLU/UKH ID card).

Bank name:
Deutsche Apotheker- und Aerztebank
IBAN: DE46300606011008814171
SWIFT code: DAAEDEDD
reason for payment: name, reg. fee TIMO XVI

SYMPOSIUM SECRETARY:

Maria Heise
Institute of Medical Immunology
Martin Luther University Halle-Wittenberg
Magdeburger Straße 2, 06112 Halle (Saale)
Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055

e-mail:immunologie@uk-halle.de

The Medical Association of Saxony-Anhalt credits this educational activity with 5 points (workshop) and 8 points (symposium). You will receive a certificate of attendance on site at the registration desk.

WE THANK OUR SPONSORS:

Becton Dickinson GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, cureVac AG, Deutsche Forschungsgemeinschaft, Deutsche Gesellschaft für Immunologie e.V., Epimune GmbH, Fluidigm GmbH, Miltenyi Biotec B.V. & Co. KG, German Academic Exchange Service (DAAD), PEPperPRINT GmbH, peptides & elephants GmbH, PeproTech, Reaction Biology Europe GmbH, Roche AG, SARSTEDT AG & Co. KG, SITC, Stadt Halle (Saale)

Special thanks to STEINTOR HALLE
Institute of Medical Immunology
Prof. Dr. Barbara Seliger
Director of FOCIS Center of Excellence

Martin-Luther-University Halle-Wittenberg
Medical Faculty
Magdeburger Straße 2
06112 Halle (Saale)
Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055
e-mail: immunologie@uk-halle.de